Synergism of small molecules targeting VDAC with sorafenib, regorafenib or lenvatinib on hepatocarcinoma cell proliferation and survival is a research paper published in European Journal of Pharmacology (2023). On theSindex it has a DataRank of 0. It has been cited 8 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: RO1 CA184456
Medical University of South Carolina South Carolina Clinical & Translational Research Institute
Grant: UL1 TR001450-SCTR
NIGMS NIH HHS
Grant: P20 GM103542
NIGMS NIH HHS
Grant: P30 GM140964
NIH HHS
Grant: S10 OD028663
NCATS NIH HHS
Grant: UL1 TR001450
NCI NIH HHS
Grant: R01 CA184456
National Institutes of Health
Grant: 3UL1TR001450-06S1
South Carolina Clinical & Translational Research Institute (SCTR)
National Institutes of Health
Grant: 5P30GM140964-02
South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling
National Institutes of Health
Grant: 1S10OD028663-01
High-Content, High-Throughput Multi-Mode Imaging System
National Institutes of Health
Grant: 3R01CA184456-02S2
VDAC Regulation of Warburg Metabolism in Hepatocarcinoma
National Institutes of Health
FWCI
0.74
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals